WEBULL
News
TRVI
11.25
+1.35%
0.15
Weekly Report: what happened at TRVI last week (0202-0206)?
Weekly Report · 1d ago
Analysts Conflicted on These Healthcare Names: Encompass Health (EHC), Hims & Hers Health (HIMS) and Trevi Therapeutics (TRVI)
TipRanks · 4d ago
Weekly Report: what happened at TRVI last week (0126-0130)?
Weekly Report · 02/02 09:07
Weekly Report: what happened at TRVI last week (0119-0123)?
Weekly Report · 01/26 09:07
Trevi announces publication of data from Phase 2b IPF chronic cough trial
TipRanks · 01/22 17:35
Trevi Therapeutics' Phase 2b CORAL Trial Results Published In JAMA Shows Nalbuphine ER Significantly Reduces Chronic Cough, With Over 60% Of Patients Achieving 50% Cough Reduction
Benzinga · 01/22 17:33
Trevi Therapeutics Reports Positive Phase 2b Results for Nalbuphine ER in IPF Chronic Cough Trial
Reuters · 01/22 17:30
TREVI THERAPEUTICS ANNOUNCES PUBLICATION OF DATA FROM THE PHASE 2B IPF CHRONIC COUGH TRIAL OF NALBUPHINE ER IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA)
Reuters · 01/22 17:30
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Artiva Biotherapeutics, Inc. (ARTV) and Oncolytics Biotech (ONCY)
TipRanks · 01/21 16:40
Weekly Report: what happened at TRVI last week (0112-0116)?
Weekly Report · 01/19 09:07
Trevi Therapeutics Inc. Files Initial Statement of Beneficial Ownership for CFO David C. Hastings
Reuters · 01/12 21:03
Weekly Report: what happened at TRVI last week (0105-0109)?
Weekly Report · 01/12 09:07
Trevi Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Dow Jones · 01/09 11:41
Trevi Therapeutics: Favorable Risk-Reward as Haduvio Advances Toward Pivotal Chronic Cough Programs and Billion-Dollar Revenue Potential
TipRanks · 01/09 11:36
HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target
Benzinga · 01/09 11:30
Trevi Therapeutics Price Target Maintained With a $19.00/Share by D. Boral Capital
Dow Jones · 01/08 13:13
Trevi Therapeutics Is Maintained at Buy by D. Boral Capital
Dow Jones · 01/08 13:13
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 01/08 13:06
D. Boral Capital Maintains Buy on Trevi Therapeutics, Maintains $19 Price Target
Benzinga · 01/08 13:04
Trevi Therapeutics Intends To Start Phase 2b Study In Participants With Refractory Chronic Cough In H1 2026, Company's Chronic Cough In Idiopathic Pulmonary Fibrosis Granted End-Of-Phase 2 Meeting With FDA
Benzinga · 01/08 12:38
More
Webull provides a variety of real-time TRVI stock news. You can receive the latest news about Trevi Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.